Key result
TUDCA prevents cardiac fibrosis and improves exercise tolerance in preclinical heart failure.
Why the study?
Cardiac fibrosis is difficult to treat clinically due to lack of understanding of molecular mechanisms and effective anti-fibrotic therapies.
Does tauroursodeoxycholic acid (TUDCA) prevent cardiac fibrosis in a mouse model of heart failure?
Population
Mouse model of heart failure with increased expression of calreticulin
Comparison
Pharmacologic inhibition of UPR pathway by TUDCA vs no inhibition
Design
Preclinical experimental study
Authors
Loading...
TUDCA attenuates fibrosis in murine HF; hypothesis-generating and should not change clinical practice.
Does tauroursodeoxycholic acid (TUDCA) prevent cardiac fibrosis in a mouse model of heart failure?
p-value: p=<0.01
Pharmacological inhibition of the unfolded protein response pathway by TUDCA prevents cardiac fibrosis and improves exercise tolerance in a mouse model of heart failure.
Groenendyk et al. (2016) studied Cardiac fibrosis and heart failure (n=162). Tauroursodeoxycholic acid (TUDCA) vs. Control diet/water was evaluated on Cardiac fibrosis (collagen deposition area) (p=<0.01). Sustained pharmacologic inhibition of the unfolded protein response pathway by tauroursodeoxycholic acid (TUDCA) prevented cardiac fibrosis and improved exercise tolerance in a mouse model of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: